Clinical Trials
Current ANZCHOG/ACCT trial activity includes:
A Phase I Study of LBH589 in Paediatric Patients with Refractory Solid Tumours Including CNS Tumours.
A Phase1/2 Study of Valproate in Combination with Interferon alpha in Relapsed, Recurrent or Progressive Neuroblastoma
A Phase II Open-Label, Randomized, Multi-centre Comparative Study of Bevacizumab-based Therapy in Paediatric Patients with Newly Diagnosed Supratentorial High-Grade Glioma.
Study 9: An international (AIEOP-BFM) collaborative treatment protocol for children and adolescents with acute lymphoblastic leukaemia (ALL)
UKALLR3: An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia
A preclinical study of the effects of the pan-Her inhibitor PF-00299804 (PF) alone, or in combination with irradiation and other chemotherapeutic agents, on the growth of CNS-PNET cell lines and human neural stem cells.
A Randomized, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Decitabine as Epigenetic Priming with Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) subjects.
Further information can be found at
Upcoming ACCT trials include:
Phase I study of vinorelbine, cyclophosphamide and Rapamycin for recurrent malignancies in children.
ANZCHOG/ACCT also contributes to the conduct of Children’s Oncology Group (COG) trials undertaken at children’s cancer centres in Australia and New Zealand.